| Description : |
Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. It shares 41 % and 48 % with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinphils. |
| Source : |
E.coli |
| Species : |
HHV8 |
| Form : |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 150mM NaCl. |
| Bio-activity : |
Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha. |
| Molecular Mass : |
Approximately 8.0 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids. |
| Protein length : |
70 |
| AA Sequence : |
LGASWHRPDKCCLGYQKRPLPQVLL SSWYPTSQLCSKPGVIFLTKRGRQV CADKSKDWVKKLMQQLPVTA |
| Endotoxin : |
Less than 1 EU/μg of rViMIP-2 as determined by LAL method. |
| Purity : |
>97% by SDS-PAGE and HPLC analyses. |
| Storage : |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution. |
| Reconstitution : |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 centigrade. Further dilutions should be made in appropriate buffered solutions. |
